Epidemiology and Management of Acquired Angioedema Due to C1 Inhibitor Deficiency

Mohammed Olaythah Alraddadi

Consultant dermatologist, University of Tabuk, Saudi Arabia.

Yousef Hussain J. Alharthi

University of Tabuk, Saudi Arabia.

Rayyan Fahad H. Altemani

University of Tabuk, Saudi Arabia.

Wejdan Mohammed S. Alshehri

University of Tabuk, Saudi Arabia.

Amal Nafea J. Alharbi

University of Tabuk, Saudi Arabia.

Raghad Saud A. Albalawi

University of Tabuk, Saudi Arabia.

Khawla Abdulrahman S. Alzahrani

University of Tabuk, Saudi Arabia.

Shuruq Mousa D. Albalawi

University of Tabuk, Saudi Arabia.

Sultan Suliman Q. Al-Ruwaili

University of Tabuk, Saudi Arabia.

Sultan Faraj Alruwaili

AL-qurayyat Gerneral Hospital, Aljouf Region, Saudi Arabia.

Mousa Amer M. Alshehri

Aseer General Hospital-Abha-Aseer Region, Saudi Arabia.

Asma Saleh S. Alruwaili

North Medical Tower Hospital-Northern Border-arar-Saudi Arabia.

Sarah Mohammad M. Ali

Alrayan College, Saudi Arabia.

Ahmad Arafat A. Abualaz

University of Jordan, Amman, Jordan.

Marah Saud Alenezi

Alfaisal University, Saudi Arabia.

*Author to whom correspondence should be addressed.


Abstract

AAE-C1-INH (acquired angioedema owing to C1-inhibitor (C1-INH) deficiency) is a dangerous illness that can lead to asphyxiation due to laryngeal edoema. Only around 1% to 2% of angioedema cases are classified as HAE or AAE, with HAE being 10 times more prevalent than AAE. The sole clinical distinction between HAE and AAE is the age at which symptoms appea, AAE-C1-INH is usually diagnosed after 40 years of age. There is no licensed therapy for AAE-C1-INH at this time. AAE-C1-INH attacks are treated with HAE-C1-INH medicines such plasma-derived C1-INH concentrate (pdC1-INH) and the bradykinin B2 receptor antagonist, icatibant. These on-demand medications are thought to be most helpful when provided early in the attack. However, there is a scarcity of published data on the efficacy and safety of AAE-C1-INH therapies.

Keywords: Angioedema, acquired angioedema due to c1 inhibitor deficiency, non - pitting edema, edema


How to Cite

Alraddadi, M. O., Alharthi, Y. H. J., Altemani, R. F. H., Alshehri, W. M. S., Alharbi, A. N. J., Albalawi, R. S. A., Alzahrani, K. A. S., Albalawi, S. M. D., Al-Ruwaili, S. S. Q., Alruwaili, S. F., Alshehri, M. A. M., Alruwaili, A. S. S., M. Ali, S. M., Abualaz, A. A. A. and Alenezi, M. S. (2021) “Epidemiology and Management of Acquired Angioedema Due to C1 Inhibitor Deficiency”, Journal of Pharmaceutical Research International, 33(57B), pp. 107–113. doi: 10.9734/jpri/2021/v33i57B34034.